Monkey Kidney Patents (Class 435/364)
-
Publication number: 20120202249Abstract: The present invention relates to constructs and methods for the production of recombinant proteins, viruses, and viral vaccines in heterologous culture systems by expressing intact genes or viral genomes under the control of a pantropic promoter in a culture system that is not considered a host to the virus so produced. The promoter/viral genome constructs are inserted into a baculovirus and expressed in mammalian non-host cells for the baculovirus.Type: ApplicationFiled: April 8, 2010Publication date: August 9, 2012Inventor: Arun K. Dhar
-
Publication number: 20120195910Abstract: The invention provides anti-PCSK9 antibodies and methods of using the same.Type: ApplicationFiled: December 21, 2011Publication date: August 2, 2012Applicant: GENENTECH, INC.Inventors: YAN WU, CECILIA CHIU, DANIEL KIRCHHOFER, ANDREW PETERSON, GANESH KOLUMAM, MONICA KONG BELTRAN, PAUL MORAN, WEI LI
-
Publication number: 20120195901Abstract: Compositions and methods for making and using anti-LPA agents, for example, monoclonal antibodies, are described.Type: ApplicationFiled: April 16, 2012Publication date: August 2, 2012Inventors: Roger A. SABBADINI, William A. GARLAND, Genevieve HANSEN, James Stephen SWANEY
-
Publication number: 20120189655Abstract: The present disclosure provides an attenuated live vaccine strain and the formulations thereof, for preventing pigs from infection of porcine reproductive and respiratory syndrome (PRRS). The preparation methods for the vaccines and the formulations are also provided. The attenuated live vaccine strain provided herein offers significant immunological protection to pigs against PRRS. The vaccine formulations of the present disclosure also have advantages in long shelf lives as well as good stability during storage.Type: ApplicationFiled: January 20, 2011Publication date: July 26, 2012Inventors: Hua Wu, Xue Leng, Zhenguang Li, Fengxue Wang
-
Publication number: 20120177675Abstract: The present invention provides a chimaeric coronavirus S protein which is based on an S protein from a coronavirus strain with restricted tissue tropism, but which comprises at least part of the S2 subunit from a coronavirus strain with extended tissue tropism, such that a virus comprising the chimaeric S protein has extended tissue tropism. The present invention also provides a virus comprising such a chimaeric S protein.Type: ApplicationFiled: July 5, 2010Publication date: July 12, 2012Applicant: INSTITUTE FOR ANIMAL HEALTHInventors: Paul Britton, Erica Bickerton, Maria Armesto
-
Publication number: 20120171160Abstract: The present invention relates generally to the use of recombinant adeno-associated viruses (rAAV) for gene delivery and more specifically to the use of rAAV to deliver genes encoding human immunodeficiency virus entry inhibitors to target cells in mammals.Type: ApplicationFiled: February 6, 2012Publication date: July 5, 2012Applicant: NATIONWIDE CHILDREN'S HOSPITAL, INC.Inventors: Philip R. Johnson, JR., Kelly Reed Clark
-
Publication number: 20120156773Abstract: A method of culturing adherent cells is provided, wherein the method comprises providing a carrier for growing the cells, comprising one or more surfaces; and one or more relief features/indentations are present on one or more of the surfaces, wherein the carrier has a length at least about 0.2 mm, a width at least about 0.2 mm, and a height in a range from about 0.012 mm to 0.5 mm; and wherein each of the relief features/indentations has a height above the surfaces in a range from about 2 to 200 ?m, and width in a range from about 20 to 200 ?m; seeding the cells on the carriers; and growing the cells on the carrier.Type: ApplicationFiled: November 2, 2011Publication date: June 21, 2012Applicant: GENERAL ELECTRIC COMPANYInventors: Reginald Donovan Smith, Scott Michael Miller, Yosang Yoon, Slawomir Rubinsztajn, Prameela Susarla
-
Publication number: 20120156722Abstract: A full-length cDNA encoding novel proteins involved in the control of cell proliferation (human Gros1-L and S) was successfully isolated from the human testis cDNA libraries. A full-length cDNA encoding the mouse homologues of the human Gros1 (mouse Gros1-L and S) was also isolated. The colony forming activity of cells exogenously expressing Gros1-L was significantly reduced, while that of cells expressing Gros1 antisense RNA was significantly increased.Type: ApplicationFiled: February 22, 2012Publication date: June 21, 2012Applicant: CHUGAI SEIYAKU KABUSHIKI KAISHAInventors: Renu Wadhwa, Takashi Sugihara, Akiko Ohide
-
Publication number: 20120148559Abstract: The invention provides deimmunized mutant proteins having reduced immunogenicity while exhibiting substantially the same or greater biological activity as the proteins of interst from which they are derived, as exemplified by mutant L-asparaginase that comprises amino acid substitutions compared to wild type L-asparaginase. The invention further provides methods for screening mutant deimmunized proteins that have substantially the same or greater biological activity as a protein of interest, and methods for reducing immunogenicity, without substantially reducing biological activity, of a protein of interest. The invention's compositions and methods are useful in, for example, therapeutic applications by minimizing adverse immune responses by the host mammalian subjects to the protein of interest.Type: ApplicationFiled: November 30, 2011Publication date: June 14, 2012Applicant: Board of Regents The University of Texas SystemInventors: George Georgiou, Jason Cantor, Tae Hyeon Yoo
-
Publication number: 20120149102Abstract: The invention provides a polypeptide comprising an agonist of a MHC Class I binding native sequence having amino acid substitution(s) and enhanced immunogenicity compared to the native sequence. The invention provides DNA encoding the polypeptide, as well as vectors and cells comprising the DNA and methods comprising the administration of the polypeptide.Type: ApplicationFiled: February 17, 2012Publication date: June 14, 2012Applicants: Human ServiceInventors: Jeffrey Schlom, Elene Barzaga, Sam Zaremba
-
Publication number: 20120142057Abstract: The present invention provides a method capable of producing a natural or recombinant protein in high yield. The present invention relates to a method of producing a polypeptide, comprising culturing a cell which strongly expresses cysteine sulfinic acid decarboxylase and has a transferred DNA encoding a desired polypeptide and thereby allowing the cell to produce the polypeptide. Hamster cysteine sulfinic acid decarboxylase, a DNA encoding the same, a recombinant vector and a transformed cell are also provided.Type: ApplicationFiled: February 8, 2012Publication date: June 7, 2012Inventors: Hisahiro Tabuchi, Satoshi Tainaka, Tomoya Sugiyama
-
Publication number: 20120134972Abstract: The present invention provides isolated polypeptides comprising a fragment of the amino acid sequence of SEQ ID NO:1, or a variant, derivative or fusion thereof, which is capable of binding specifically to and lysing cells of Clostridium difficile, wherein the polypeptide exhibits greater lytic activity on cells of Clostridium difficile than the polypeptide of SEQ ID NO: 1. The invention further provides means for producing the same, methods for killing bacterial cells such as cells of Clostridium difficile, as well as methods for diagnosing, treating and preventing diseases and conditions associated with infection of the same.Type: ApplicationFiled: May 26, 2010Publication date: May 31, 2012Applicant: PLANT BIOSCIENCE LIMITEDInventors: Melinda Mayer, Arjan Narbad
-
Publication number: 20120122150Abstract: The present invention provides methods for stabilizing a biological sample for analysis. The invention more particularly provides methods combining heat treatment and chemical fixation of biological samples in order to maintain protein primary structure and post-translational modifications, such as protein phosphorylations.Type: ApplicationFiled: June 8, 2010Publication date: May 17, 2012Applicant: DENATOR AKTIEBOLAGInventors: Mats Borén, Karl Skdöld, Marcus Svensson
-
Publication number: 20120114691Abstract: The present invention provides vectors that contain and express in vivo the genes encoding VP2 and VP5 of African Horse Sickness Virus or an epitope thereof that elicits an immune response in a horse against African horse sickness virus, compositions comprising said vectors, methods of vaccination against African horse sickness virus, and kits for use with such methods and compositions.Type: ApplicationFiled: January 25, 2012Publication date: May 10, 2012Inventors: Jules Maarten Minke, Jean-Christophe Audonnet, Alan John Guthrie, Nigel James Maclachlan, Jiansheng Yao
-
Publication number: 20120100140Abstract: A method of producing Fc-containing polypeptides, such as antibodies, having stabilized Fc regions is provided, together with stabilized Fc polypeptides produced according to these methods as well as methods of using such antibodies as therapeutics.Type: ApplicationFiled: January 22, 2010Publication date: April 26, 2012Applicant: BIOGEN IDEC MA INC.Inventors: Christopher L. Reyes, Eric Chan, Frederick R. Taylor, Ellen Garber, Brian Robert Miller, Stephen Demarest, Scott Glaser
-
Publication number: 20120082693Abstract: The invention relates to the use of proteins and peptides coded by the genome of the isolated or purified strain of severe acute respiratory syndrome (SARS)-associated coronavirus, resulting from sample reference number 031589 and, in particular, to the use of protein S and the derivative antibodies thereof as diagnostic reagents and as a vaccine.Type: ApplicationFiled: July 20, 2011Publication date: April 5, 2012Inventors: Sylvie VAN DER WERF, Nicolas Escriou, Bernadette Crescenzo-Chaigne, Jean-Claude Manuguerra, Frederik Kunst, Benoît Callendret, Jean-Michel Betton, Valérie Lorin, Sylvie Gerbaud, Ana Maria Burguiere, Saliha Azebi, Pierre Charneau, Frédéric Tangy, Chantal Combredet, Jean-François Delagneau, Monique Martin
-
Publication number: 20120083442Abstract: The present invention provides binding agents comprising peptides capable of binding myostatin and inhibiting its activity. In one embodiment the binding agent comprises at least one myostatin-binding peptide attached directly or indirectly to at least one vehicle such as a polymer or an Fc domain. The binding agents of the present invention produced increased lean muscle mass when administered to animals and decreased fat to muscle ratios. Therapeutic compositions containing the binding agents of the present invention are useful for treating muscle-wasting disorders and metabolic disorders including diabetes and obesity.Type: ApplicationFiled: December 2, 2011Publication date: April 5, 2012Applicant: AMGEN INC.Inventors: HQ HAN, HOSUNG MIN, THOMAS CHARLES BOONE
-
Publication number: 20120077268Abstract: The present invention relates to a process for culturing animal cells, e.g., human, diploid anchorage-dependent cells, in the absence of exogenous components of primary animal origin. In particular, the invention provides cell culture media substantially free of exogenous components of primary and secondary animal origin which comprises at least one, more preferably several, exogenous animal-free growth factors. The present invention also relates to a process for cultivating animal cells using a protease of non-animal origin for passaging cells.Type: ApplicationFiled: October 10, 2011Publication date: March 29, 2012Applicant: GlaxoSmithKline Biologicals, s.a.Inventors: Brigitte Ghislaine Louise Aerts, Yves Jules Maurice Ghislain, Marie-Monique Jane Gonze, Isabelle Solange Lucie Knott, Carine Maggetto
-
Publication number: 20120070868Abstract: Recombinant microbial cells are provided which have been engineered to produce fatty acid derivatives having linear chains containing an odd number of carbon atoms by the fatty acid biosynthetic pathway. Also provided are methods of making odd chain fatty acid derivatives using the recombinant microbial cells, and compositions comprising odd chain fatty acid derivatives produced by such methods.Type: ApplicationFiled: September 14, 2011Publication date: March 22, 2012Applicant: LS9, INC.Inventors: Grace J. Lee, John R. Haliburton, Zhihao Hu, Andreas W. Schirmer
-
Publication number: 20120071859Abstract: The invention provides an isolated or purified nucleic acid comprising a nucleotide sequence encoding a nuclear factor of activated T-cells (NFAT) promoter operatively associated with a nucleotide sequence encoding IL-12. The invention also provides a nucleic acid comprising a nucleotide sequence encoding a nuclear factor of activated T-cells (NFAT) promoter operatively associated with a nucleotide sequence encoding IL-12, wherein the NFAT promoter is located 3? of the nucleotide sequence encoding IL-12. Also provided are related recombinant expression vectors, host cells, populations of cells, and pharmaceutical compositions. The invention further provides the use of the inventive nucleic acids or related materials in the treatment or prevention of cancer or an infectious disease in a mammal and in the induction of IL-12 expression in a mammal.Type: ApplicationFiled: April 22, 2010Publication date: March 22, 2012Inventors: Richard A. Morgan, Steven A. Rosenberg, Ling Zhang, Nicholas P. Restifo
-
Publication number: 20120058136Abstract: Compositions comprising gp350 variant DNA and amino acid sequences are provided, as are vectors and host cells containing such sequences. Also provided is a process for producing homogeneous gp350 protein recombinantly and in the absence of production of gp220 protein, pharmaceutical compositions containing such protein and prophylactic treatments making use of such proteins.Type: ApplicationFiled: May 26, 2011Publication date: March 8, 2012Applicant: MedImmune, LLCInventors: Richard SPAETE, Winthrop Jackman
-
Publication number: 20120060230Abstract: Disclosed herein are methods and compositions for modulating the expression of a HLA locus or for selectively deleting or manipulating a HLA locus or HLA regulator.Type: ApplicationFiled: July 21, 2011Publication date: March 8, 2012Inventors: Trevor Collingwood, Laurence J.N. Cooper, Philip D. Gregory, Michael C. Holmes, Jeffrey C. Miller, Edward J. Rebar, Andreas Reik, Fyodor Urnov
-
Publication number: 20120040399Abstract: The present invention relates to improved methods for the production of viral particles, viral vector particles and recombinant proteins. In particular, the invention relates to improved methods for the production of recombinant polyomaviral vector particles and polyomaviral vector production cell lines. More in particular, the invention relates to methods for the production of simian polyomaviral vector particles such as simian virus 40 (SV40) viral vector particles. The invention also relates to compositions comprising viral vectors and uses thereof and viral vector particles to treat genetic disorders, transplant rejection, autoimmune diseases, infectious diseases, allergies or cancer. The invention also relates to methods for the production of recombinant proteins in mammalian cells and methods to enhance the production of recombinant proteins in mammalian cells.Type: ApplicationFiled: April 22, 2010Publication date: February 16, 2012Applicant: Amarna Holding B.V.Inventor: Walter Gerhardus De Vries
-
Publication number: 20120040917Abstract: The present invention relates to compositions and methods for preparing splice variants of TNFalpha receptor (TNFR) in vivo or in vitro, and the resulting TNFR protein variants. Such variants may be prepared by controlling the splicing of pre-mRNA molecules and regulating protein expression with splice switching oligonucleotides or splice switching oligomers (SSOs). The preferred SSOs according to the invention target exon 7 or 8 of TNFR1 (TNFRSF1A) or TNFR2 (TNFRSF1A) pre-mRNA, typically resulting in the production of TNFR variants which comprise a deletion in part or the entire exon 7 or 8 respectfully. SSOs targeting exon 7 are found to result in a soluble form of the TNFR, which has therapeutic benefit for treatment of inflammatory diseases. The SSO's are characterized in that they are substantially incapable or incapable of recruiting RNaseH.Type: ApplicationFiled: December 3, 2010Publication date: February 16, 2012Inventors: HENRIK ØRUM, PETER L. SAZANI
-
Publication number: 20120034691Abstract: Provided herein are nucleic acid sequences and polypeptides encoding a genetically encoded calcium indicator (GECI). Also provided are vectors and cells comprising the nucleic acid sequences and/or polypeptides. Kits comprising the nucleic acid sequences, polypeptides, vectors, cells and combinations thereof are also provided. Also provided herein are methods of screening for G-protein coupled receptor (GPCR) agonists and antagonists and methods of monitoring neural activity using the GECIs.Type: ApplicationFiled: July 27, 2011Publication date: February 9, 2012Inventors: Loren Lee Looger, Lin Tian
-
Publication number: 20120028900Abstract: Provided herein are methods and compositions for producing Factor VIII proteins. Such methods include introducing into a cell a nucleic acid molecule encoding a Factor VIII protein operably linked to a promoter, wherein the promoter is characterized by the ability to produce commercially viable Factor VIII protein; and incubating the cell under conditions for producing commercially viable Factor VIII protein. Also provided are nucleic acid molecules which encode a Factor VIII protein operably linked to a Chinese hamster elongation factor 1-? (CHEF1) promoter, which may be used in the methods provided herein.Type: ApplicationFiled: June 3, 2011Publication date: February 2, 2012Inventors: RANDAL J. KAUFMAN, STEVEN W. PIPE, MICHAEL GRIFFITH
-
Publication number: 20120015888Abstract: The invention provides T cell receptors (TCRs) having antigenic specificity for a cancer antigen, e.g., tyrosinase. Also provided are related polypeptides, proteins, nucleic acids, recombinant expression vectors, isolated host cells, populations of cells, and pharmaceutical compositions. The invention further provides a method of detecting the presence of cancer in a host and a method of treating or preventing cancer in a host using the inventive TCRs or related materials.Type: ApplicationFiled: January 25, 2010Publication date: January 19, 2012Inventors: Steven A. Rosenberg, Richard A. Morgan, Timothy L. Frankel, Peter Peng
-
Publication number: 20120015840Abstract: The present invention relates to a method for generating an RNA library or a (poly)peptide library comprising the steps of: (a) providing one or more nucleic acid molecules each comprising i) two or more coding elements (A) each giving rise to an RNA molecule upon transcription and/or a (poly)peptide upon transcription and translation; and ii) linking elements (B) arranged according to the general formula of B(AB)2+n, wherein said linking elements comprise one or more sequence motifs not found in said two or more coding elements allowing specific disruption of the linking elements (B); (b) cloning the nucleic acid molecule of step (a) into a vector; (c) transforming a host cell with the vector obtained in step (b) and propagating said transformed cell; (d) preparing vector DNA from the transformed and propagated cells of step (c); (e) (i) disrupting the vector DNA obtained in step (d) with one or more agents recognizing said one or more sequence motifs of the linking elements or (ii) performing an amplificatiType: ApplicationFiled: January 22, 2010Publication date: January 19, 2012Inventor: Michael Lebens
-
Publication number: 20120009190Abstract: The invention provides isolated Pre-Ligand Assembly Domain (PLAD) polypeptides comprising an amino acid sequence of a domain (e.g., a Fibronectin Ill-like domain) of an IL-17 Receptor (IL-17R) family member, wherein the PLAD polypeptide inhibits multimerization of a receptor complex comprising an IL-17R family member. Also provided are isolated PLAD-binding polypeptides, e.g., antibodies and avimers, which specifically bind to a PLAD polypeptide described herein. Related chimeric proteins, conjugates, nucleic acids, vectors, and host cells are provided herein. Further provided are methods of treating an inflammatory or autoimmune disease, methods of inhibiting IL-17-mediated signal transduction, methods of inhibiting IL-17 ligand binding, methods of inhibiting multimerization of IL-17R complexes, and methods of inhibiting the production of at least one cytokine, chemokine, matrix metalloproteinase, or other molecule associated with IL-17 signal transduction are provided.Type: ApplicationFiled: April 20, 2008Publication date: January 12, 2012Applicant: AMGEN INC.Inventors: Sarah L. Gaffen, Fang Shen, Walter Hanel, Jill Kramer, James P. Malone, Michael Wittekind, Raymond Paxton
-
Patent number: 8088600Abstract: The present invention relates to at least one novel cynomolgus IL-13 muteins (Mut-IL-13) proteins, antibodies, including isolated nucleic acids that encode at least one Mut-IL-13 protein or antibody, Mut-IL-13 vectors, host cells, transgenic animals or plants, and methods of making and using thereof, including therapeutic compositions, methods and devices.Type: GrantFiled: October 12, 2007Date of Patent: January 3, 2012Assignee: Centocor Ortho Biotech Inc.Inventors: Karyn O'Neil, Leslee Conrad, Dusti Fisher
-
Publication number: 20110318808Abstract: The present invention relates to potato virus NIa protease variants or fragments thereof, polynucleotides encoding them, and methods of making and using the foregoing.Type: ApplicationFiled: April 14, 2011Publication date: December 29, 2011Inventors: Ellen Chi, Michael Hunter, Ronald Swanson
-
Publication number: 20110319337Abstract: The present disclosure provides compositions, pharmaceutical preparations, kits and methods for inhibiting cell proliferation by contacting a cell expressing Fzd8 with a truncated Wnt2 polypeptide which acts as a dominant negative inhibitor of Fzd8 signaling. The present disclosure provides compositions, kits and methods for the detection of cancer by determining the level of Fzd8 and/or Wnt2 expression in a cell.Type: ApplicationFiled: December 30, 2009Publication date: December 29, 2011Inventors: Dawn Bravo, Liang You, Zhidong Xu, Biao He, David M. Jablons
-
Publication number: 20110313029Abstract: The allelic variants or mutations in three genes: GNPTAB, GNPTG and NAGPA, that correlate with stuttering in humans, as well as the encoded mutated polypeptides and related vectors, host cells, antibodies, antibody-producing cell lines and methods of diagnosing, prognosticating and treating stuttering are provided.Type: ApplicationFiled: February 8, 2010Publication date: December 22, 2011Applicants: Centre of Excellence in Molecular Biology Together with all Allied Components, University of Punjab, The United States of America, as represented by the Secretary, Dept. of Health and Human ServicesInventors: Dennis T. Drayna, Changsoo Paul Kang, Sheikh Riazuddin
-
Publication number: 20110311615Abstract: The present invention deals with a modified polypeptide comprising three contiguous segments N, L and C represented by the formula N?L?C and comprising: a N-helix region of gp41 (N), a C-helix region of gp41 (C), and a connecting loop comprising a synthetic linker (L) between the N and C-helices, the linker replacing amino acids 593-617 of gp41, the numbering scheme being based upon the prototypic isolate HIV-1 HxB2 Clade B strain, said polypeptide comprising the calveolin-1 neutral izing and 98.6 D epitopes, but not 2F5 and 4E10 epitopes, not the fusion peptide, the polypeptide having a minimal immunogenic cross-reactivity with human interleukin 2 (IL2).Type: ApplicationFiled: February 8, 2010Publication date: December 22, 2011Applicant: MYMETICS CORPORATIONInventors: Sylvain Fleury, Nicolas Mouz, Marie-Gaelle Roger
-
Publication number: 20110314564Abstract: The present invention relates to enzymes which are able to hydrolyse phenylureas, carbamates, and/or organophosphates, as well as polynucleotides encoding these enzymes. The present invention also relates to methods of hydrolysing phenylureas, carbamates, and/or organophosphates.Type: ApplicationFiled: July 8, 2009Publication date: December 22, 2011Applicant: Commonwealth Scientific and Industrial Research OrganisationInventors: Jeevan L. Khurana, Colin J. Jackson, Colin Scott, Gunjan Pandey, Robyn J. Russell, John G. Oakeshott
-
Publication number: 20110306090Abstract: The present invention describes new mammalian expression vectors comprising a novel combination of regulatory elements and one or more selection marker gene(s). The vector allows for incorporation of at least one, preferably two or more genes of interest, its/their subsequent expression, and for selection of transfected cells using, e.g., G418 and/or MTX. The pDGP?GOI vector as an example for a mammalian expression vector according to the present invention exhibits a 9555 bp sequence, one strand of which is represented by SEQ ID NO:2.Type: ApplicationFiled: December 18, 2009Publication date: December 15, 2011Applicant: LEK PHARMACEUTICALS D.D.Inventors: Andrej Francky, Dominik Gaser
-
Publication number: 20110301092Abstract: The use of a non-glycanated form of a polypeptide including an amino acid sequence having at least 90% amino acid identity with an amino acid sequence selected from the group consisting of SEQ ID No 1 and SEQ ID No 2 for manufacturing a medicament for preventing or treating a cancer.Type: ApplicationFiled: October 24, 2008Publication date: December 8, 2011Applicant: INSTITUT PASTEUR DE LILLEInventors: Philippe Lassalle, Bogdan Grigoriu, Florence Depontieu
-
Publication number: 20110294748Abstract: The present invention relates to insulin-like growth factor 1 receptor binding peptides, polynucleotides encoding them, and methods of making and using the foregoing.Type: ApplicationFiled: May 25, 2011Publication date: December 1, 2011Inventors: Michael Diem, Karyn O'Neil
-
Publication number: 20110293632Abstract: The present invention concerns polypeptides comprising a variant Fc region. More particularly, the present invention concerns Fc region-containing polypeptides that have altered effector function as a consequence of one or more amino acid modifications in the Fc region thereof.Type: ApplicationFiled: November 30, 2007Publication date: December 1, 2011Applicant: Genentech, Inc.Inventor: Leonard Presta
-
Publication number: 20110289610Abstract: An HCV/GBV-B chimeric virus which maintains the replication function of HCV and is capable of infecting tamarin is disclosed in order to construct an HCV animal model which can be used as a development or evaluation system for therapeutic agents for HCV. The HCV/GBV-B chimeric RNA comprises an RNA of hepatitis C virus and an RNA of GB virus-B, wherein the RNA of hepatitis C virus comprises an RNA encoding leucine at the 1804th position and lysine at the 1966th position in the amino acid sequence of the polyprotein of hepatitis C virus.Type: ApplicationFiled: July 15, 2009Publication date: November 24, 2011Inventors: Noboru Maki, Kenichi Mori, Hiromi Fukai
-
Publication number: 20110281803Abstract: An isolated polypeptide inhibitor of SuIfIa having a sequence which is a variant of Sulf1a, and which lacks sulfatase activity and lacks the ability to bind to the surface of a cell. The polypeptide inhibitor of SuIf1a may be the alternatively spliced isoform SuIf1b. An isolated polypeptide inhibitor of Sulf2a having a sequence which is a variant of Sulf2a, and which lacks sulfatase activity and lacks the ability to bind to the surface of a cell. The polypeptide inhibitor of Sulf2a may be the alternatively spliced isoform Sulf2b. A method of combating a cancer in which Wnt signalling is upregulated or of treating ischaemia in a patient, the method comprising administering to the patient a polypeptide inhibitor of Sulf1a and/or Sulf2a. A method of combating a cancer in which Wnt signalling is not upregulated, the method comprising administering to the patient an inhibitor of Sulf1b and/or Sulf2b.Type: ApplicationFiled: November 10, 2008Publication date: November 17, 2011Inventor: Gurtej Kaur Dhoot
-
Publication number: 20110274623Abstract: A protein scaffold based on a consensus sequence of fibronectin type III (FN3) proteins, such as the tenth FN3 repeat from human fibronectin (human Tenascin), including isolated nucleic acids that encode a protein scaffold, vectors, host cells, and methods of making and using thereof, exhibit enhanced thermal and chemical stability while presenting six modifiable loop domains which can be engineered to form a binding partner capable of binding to a target for applications in diagnostic and/or therapeutic compositions, methods and devices.Type: ApplicationFiled: April 29, 2011Publication date: November 10, 2011Inventor: Steven Jacobs
-
Publication number: 20110263484Abstract: The present invention relates to single chain Fc Type III Interferon fusion proteins and methods of using same. The single chain Fc Type III Interferon fusion proteins comprise at least one Type III Interferon, two Fc regions and at least one linker, can be produced in a variety of single chain configurations, and are effector function minus or have a substantially reduced effector function.Type: ApplicationFiled: October 13, 2009Publication date: October 27, 2011Inventors: Margaret D. Moore, Michael G. Dodds, Paul O. Sheppard, Henrik Andersen
-
Publication number: 20110262591Abstract: The present invention relates to novel polynucleotide sequences comprising genes that encode novel lipolytic enzymes, as well asfunctional equivalents of the gene or the amino acid sequences with high homology thereto. The invention also relates to methods of using these lipolytic enzymes in industrial processes, for example in the dairy or baking industry.Type: ApplicationFiled: February 26, 2009Publication date: October 27, 2011Inventors: Jan Metske Laan Van Der, Yulia M. Efimova, Karin Turk, Albertus Alard Van Dijk, Natalja Alekseevna Cyplenkova, Margot Elisabeth Francoise Schooneveld-Bergmans, Arie Gerrit Terdu, Arjen Sein
-
Publication number: 20110263585Abstract: The present invention relates to polypeptides, preferably from Drosophila melanogaster (DmShaI) as target for insecticides.Type: ApplicationFiled: November 5, 2009Publication date: October 27, 2011Applicant: BASF SEInventors: Paul Bernasconi, John Dorsch, Lynn Stam, Scott Zitko, Nancy B. Rankl, Mike Griswold, Franz-Josef Braun, Gang Lu, Robert D. Kirkton, Barbara Wedel, Joachim Dickhaut, Angela Hofhine, Jennifer Zink, Fae Malone, Daniel Houtz, Steffen Gross, Ramani Kandasamy, Damian London, Thomas M. Gurganus
-
Publication number: 20110223659Abstract: The invention provides compositions and methods for detecting the presence of SARS-coronavirus, for screening anti-SARS coronavirus agents and vaccines, and for reducing infection with plus-strand RNA viruses such as SARS-coronavirus.Type: ApplicationFiled: December 7, 2010Publication date: September 15, 2011Inventors: David R. Scholl, Joseph D. Jollick, Laura Gillim-Ross, Jill Taylor, David E. Wentworth
-
Publication number: 20110217772Abstract: The present invention relates to animal protein free cell culture media comprising a combination of non-animal derived peptides derived from soy hydrolysate and yeast hydrolysate. The invention also provides an animal protein free culture process, wherein cells are cultivated, propagated and passaged without animal-derived components. This process is useful for cultivating cells, such as recombinant cells or cells infected with a virus, and for production biological products by cell culture processes under conditions devoid of animal protein components.Type: ApplicationFiled: May 6, 2011Publication date: September 8, 2011Applicants: Baxter International Inc., Baxter Healthcare S.A.Inventors: Manfred Reiter, Wolfgang Mundt, Leopold Grillberger, Barbara Kraus
-
Publication number: 20110212164Abstract: The present invention relates to polynucleotides encoding immunogenic HIV type C Pol, Gag- and/or Env-containing polypeptides. Uses of the polynucleotides in applications including DNA immunization, generation of packaging cell lines, and production of Pol, Gag- and/or Env-containing proteins are also described.Type: ApplicationFiled: May 2, 2011Publication date: September 1, 2011Applicant: Novartis Vaccines & Diagnostics, Inc.Inventors: Susan BARNETT, Jan Zur Megede
-
Publication number: 20110206683Abstract: The invention relates to a preservation composition, a formulation comprising a preservation mixture of glutamate, a saccharide, and a polymer. Said preservation mixture is advantageously used for the preservation of a biological compound.Type: ApplicationFiled: October 22, 2009Publication date: August 25, 2011Applicant: DE STAAT DER NEDERLANDEN, VERT. DOOR DE MINISTER VAN VWSInventors: Cornelis Wilhelmus Van Ingen, Chen Shu-hui Tan
-
Publication number: 20110201087Abstract: The present invention relates to virus growth media that improve the yield of alpha-herpesviruses (e.g., HSV-2) grown in cell cultures. The growth media of the invention include two additives, a disaccharide and a lipid mixture, that can be added to serum-free or serum-enriched growth media to improve the efficiency of virus production. The invention further provides methods of producing alpha-herpesviruses (e.g., HSV-2) in such growth media.Type: ApplicationFiled: August 11, 2009Publication date: August 18, 2011Applicant: Sanofi Pasteur Biologics Co.Inventors: Simon Delagrave, Rachid Oubelaid, John Hamberger